Karen S Anderson1, Garrick Wallstrom2, Hilde Langseth3, Marshall Posner4, Julia N Cheng2, Rizwan Alam2, Diego Chowell5, Ingegerd E Furre6, Jon Mork7. 1. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States. Electronic address: Karen.Anderson.1@asu.edu. 2. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States. 3. Cancer Registry of Norway, Institute of Population-based Cancer Research,; Department of Research, Oslo, Norway. 4. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, United States. 5. Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States; Simon A. Levin Mathematical, Computational, and Modeling Sciences Center, Arizona State University, Tempe, AZ, United States. 6. Department of Pathology, Oslo University Hospital, Oslo, Norway. 7. Department of Otolaryngology, Oslo University Hospital, Oslo, Norway.
Abstract
OBJECTIVE: The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. METHODS: We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3years before diagnosis (range, 0.1-14.9years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. RESULTS: HPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3-7.2, p<0.0001). Abs to E2 were strongly associated with cases 0-2years pre- diagnosis (OR, 150.1; 95% CI, 27.4-1040.0, p<0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6-0.9, p=0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7-200.0, p<0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6-53.4) compared with controls (p<0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6-99.6, p<0.001). CONCLUSIONS: HPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.
OBJECTIVE: The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. METHODS: We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3years before diagnosis (range, 0.1-14.9years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. RESULTS:HPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3-7.2, p<0.0001). Abs to E2 were strongly associated with cases 0-2years pre- diagnosis (OR, 150.1; 95% CI, 27.4-1040.0, p<0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6-0.9, p=0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7-200.0, p<0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6-53.4) compared with controls (p<0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6-99.6, p<0.001). CONCLUSIONS:HPV16Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.
Authors: Krystle A Lang Kuhs; Michael Pawlita; Sandra P Gibson; Nicole C Schmitt; Sumita Trivedi; Athanassios Argiris; Aimée R Kreimer; Robert L Ferris; Tim Waterboer Journal: Cancer Epidemiol Date: 2016-03-21 Impact factor: 2.984
Authors: Arya Amini; Jagar Jasem; Bernard L Jones; Tyler P Robin; Jessica D McDermott; Shilpa Bhatia; David Raben; Antonio Jimeno; Daniel W Bowles; Sana D Karam Journal: Oral Oncol Date: 2016-03-12 Impact factor: 5.337
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Elaine M Smith; Michael Pawlita; Linda M Rubenstein; Thomas H Haugen; Eva Hamsikova; Lubomir P Turek Journal: Int J Cancer Date: 2010-07-01 Impact factor: 7.396
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Sanjana Balachandra; Samuel B Kusin; Rebecca Lee; James-Michael Blackwell; Jasmin A Tiro; Lindsay G Cowell; Cheng-Ming Chiang; Shwu-Yuan Wu; Sanskriti Varma; Erika L Rivera; Helen G Mayo; Lianghao Ding; Baran D Sumer; Jayanthi S Lea; Aditya Bagrodia; Linda M Farkas; Richard Wang; Carole Fakhry; Kristina R Dahlstrom; Erich M Sturgis; Andrew T Day Journal: Cancer Date: 2020-12-03 Impact factor: 6.860
Authors: Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily Journal: Clin Exp Med Date: 2022-02-23 Impact factor: 3.984
Authors: Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui Journal: Front Immunol Date: 2021-01-08 Impact factor: 7.561